DK1313716T3 - Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister - Google Patents

Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister

Info

Publication number
DK1313716T3
DK1313716T3 DK01963733T DK01963733T DK1313716T3 DK 1313716 T3 DK1313716 T3 DK 1313716T3 DK 01963733 T DK01963733 T DK 01963733T DK 01963733 T DK01963733 T DK 01963733T DK 1313716 T3 DK1313716 T3 DK 1313716T3
Authority
DK
Denmark
Prior art keywords
alkyl
unsubstituted
oxazolyl
substituted
acid derivatives
Prior art date
Application number
DK01963733T
Other languages
English (en)
Inventor
Sarah Beth Jones
Leonard Larry Junio Winneroski
Alexander Glenn Godfrey
Yanping Xu
Dawn Alisa Brooks
James Ray Mccarthy
Christopher John Rito
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1313716T3 publication Critical patent/DK1313716T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DK01963733T 2000-08-23 2001-08-23 Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister DK1313716T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (1)

Publication Number Publication Date
DK1313716T3 true DK1313716T3 (da) 2007-08-27

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01963733T DK1313716T3 (da) 2000-08-23 2001-08-23 Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister

Country Status (26)

Country Link
US (2) US6930120B2 (da)
EP (1) EP1313716B1 (da)
JP (1) JP2004506721A (da)
KR (1) KR20030027054A (da)
CN (1) CN1471517A (da)
AT (1) ATE361283T1 (da)
AU (1) AU2001284659A1 (da)
BR (1) BR0113409A (da)
CA (1) CA2418104A1 (da)
CY (1) CY1107679T1 (da)
CZ (1) CZ2003482A3 (da)
DE (1) DE60128239T2 (da)
DK (1) DK1313716T3 (da)
EA (1) EA200300286A1 (da)
EC (1) ECSP034504A (da)
ES (1) ES2286137T3 (da)
HU (1) HUP0300857A3 (da)
IL (1) IL154110A0 (da)
MX (1) MXPA03001558A (da)
NO (1) NO20030729L (da)
NZ (1) NZ523804A (da)
PL (1) PL360744A1 (da)
PT (1) PT1313716E (da)
SK (1) SK1872003A3 (da)
WO (1) WO2002016331A1 (da)
ZA (1) ZA200300570B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284658A1 (en) * 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
WO2002016332A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
MXPA03010435A (es) * 2001-05-15 2004-03-09 Hoffmann La Roche Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
WO2004005266A1 (en) 2002-07-03 2004-01-15 F. Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
EP1537091B1 (en) 2002-08-30 2010-10-06 F. Hoffmann-La Roche AG Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
CN100577660C (zh) 2002-09-12 2010-01-06 霍夫曼-拉罗奇有限公司 作为ppar激动剂用于治疗糖尿病的n-取代-1h-吲哚-5-丙酸化合物
TWI343915B (en) 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
PL210871B1 (pl) 2002-11-08 2012-03-30 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środki farmaceutyczne i zastosowanie pochodnych oksazolu
ES2312819T3 (es) 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MXPA06001916A (es) * 2003-08-20 2006-05-17 Lilly Co Eli Compuestos, metodos y formulaciones para el suministro oral de un compuesto peptidico similar a glucagona (glp)-i o un peptido agonista del receptor de melanocortina 4 (mc4).
ATE350369T1 (de) * 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
WO2006057448A1 (ja) * 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO1998007699A1 (fr) * 1996-08-19 1998-02-26 Japan Tobacco Inc. Derives d'acide propionique et applications de ces derives
ATE451346T1 (de) 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
PT1206457E (pt) 1999-08-27 2004-03-31 Lilly Co Eli Derivados de diaril-oxa(tia)zol e seu uso como moduladores dos ppars
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
WO2002016332A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001284658A1 (en) 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
IL154110A0 (en) 2003-07-31
ZA200300570B (en) 2004-04-21
CZ2003482A3 (cs) 2003-05-14
HUP0300857A3 (en) 2007-03-28
KR20030027054A (ko) 2003-04-03
EP1313716B1 (en) 2007-05-02
DE60128239T2 (de) 2008-01-10
US7345070B2 (en) 2008-03-18
MXPA03001558A (es) 2003-06-06
CA2418104A1 (en) 2002-02-28
ES2286137T3 (es) 2007-12-01
US20050245584A1 (en) 2005-11-03
CY1107679T1 (el) 2013-04-18
NO20030729L (no) 2003-04-02
JP2004506721A (ja) 2004-03-04
ATE361283T1 (de) 2007-05-15
PT1313716E (pt) 2007-07-11
AU2001284659A1 (en) 2002-03-04
US20040097590A1 (en) 2004-05-20
BR0113409A (pt) 2003-07-01
EP1313716A1 (en) 2003-05-28
ECSP034504A (es) 2003-04-25
NO20030729D0 (no) 2003-02-14
WO2002016331A1 (en) 2002-02-28
PL360744A1 (en) 2004-09-20
SK1872003A3 (en) 2003-07-01
CN1471517A (zh) 2004-01-28
HUP0300857A2 (hu) 2003-10-28
NZ523804A (en) 2004-09-24
DE60128239D1 (de) 2007-06-14
EA200300286A1 (ru) 2003-08-28
US6930120B2 (en) 2005-08-16

Similar Documents

Publication Publication Date Title
DK1313716T3 (da) Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
AU2001284658A1 (en) Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
EP1357115A4 (en) ALKANOIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
SE423812B (sv) Forfarande for framstellning av terapeutiskt aktiva derivat av azetidin-2-karboxylsyra, prolin och pipekolinsyra
PT96255A (pt) Processo para a preparacao de novos derivados da 1-naftil-piperazina
DK0540051T3 (da) Aromatiske amidinderivater og salte deraf
PE20000625A1 (es) Derivados de acido oxiiminoalcanoico
AR037898A1 (es) Compuesto de benzamida, uso de un compuesto de benzamida en la fabricacion de un medicamento, proceso para su preparacion y composicion farmaceutica que lo comprende
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
WO2002038553A3 (en) Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists
NO991957D0 (no) Nye benzotiofen, benzofuran og indolforbindelser, en fremgangsmÕte ved deres fremstilling og farmas°ytiske sammensetninger inneholdende dem
EP1394154A4 (en) HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID
KR900001684A (ko) (1-히드록시-2- 피페리딜알킬)-인돌-2-온, 2-퀴놀리논, 2- 벤조[b] 아자피논, 벤즈이미다졸-2-온 및 퀴나졸린-2-온의 유도체, 그의 제조 및 치료요법에서의 그의 적용
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
WO2002028844A1 (fr) Dérivés thiazole ou oxazole
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
DK0508740T3 (da) Thiazolidindionderivater, deres fremstilling og anvendelse.
SE8006365L (sv) Cyklohexankarboxylsyraderivat
NO994209L (no) Fremgangsmaate for fremstilling av 2-ÄÄ(2-pyridinyl)metylÜsulfinylÜ-1H-benzimidazoler og nye forbindelser til anvendelse for dette formaal
DK1559714T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-aminothiophenderivater og 3-aminothiophenderivater
DK1023898T3 (da) Cyanoindoler som serotonin-genoptagningsinhibitorer og som 5-HT2c-receptorligander
NO20003431D0 (no) Nye metalloproteaseinhibitorer, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
DK272684D0 (da) Tetrahydro-beta-carbolin-derivater og fremgangsmaade til fremstilling deraf
DK1674101T3 (da) Benzo[b]pyrano[3,2-h]acridin-7-on-kanelsyrederivater, fremgangsmåde til fremstilling heraf og farmaceutiske samrnensætninger indeholdende disse.